We are live on ! Find out more
SURF

Surface Oncology, Inc. Common Stock
SURF

Delisted

SURF was delisted on the 7th of September, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Surface Oncology, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

32.04% less ownership

Funds ownership: 32.04% → 0% (-32%)

100% less funds holding

Funds holding: 61 → 0 (-61)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $16.9M

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 61

Holders
–
Holders Change
-61
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
61
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
-$4.25M
2
Atlas Venture Associates IX
Atlas Venture Associates IX
Massachusetts
-$2.56M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$2.01M
4
ARK Investment Management
ARK Investment Management
Florida
-$1.23M
5
DAFNA Capital Management
DAFNA Capital Management
California
-$957K

SURF Hedge Fund Activity: Q3 2023 in Review

0 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q3 2023, worth a combined $0 — down 100% from $16.9M a quarter earlier.

Sellers outnumbered buyers: 61 funds closed out of SURF and 0 opened new positions — a net loss of 61 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Armistice Capital, exiting entirely with an estimated $4.25M sold.

  • 0 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q3 2023, down from 61 in Q2 2023.
  • Funds reported $0 of Surface Oncology, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Surface Oncology, Inc. Common Stock positions in Q3 2023 and 61 closed out, a net change of -61 holders.
  • The largest Surface Oncology, Inc. Common Stock seller in Q3 2023 was Armistice Capital, an estimated $4.25M sold.

Based on aggregated 13F filings for Q3 2023.